LDL-C Polygenic Risk Score and ASCVD in Monogenic Familial Hypercholesterolemia
Elevated LDL-C polygenic scores associated with higher LDL-C levels and increased risk for ASCVD in patients with monogenic familial hypercholesterolemia.
Elevated LDL-C polygenic scores associated with higher LDL-C levels and increased risk for ASCVD in patients with monogenic familial hypercholesterolemia.
Associations between pathogenic variant positivity and 4-single nucleotide polymorphism score were established in patients with familial hypercholesterolemia in response to lipid-lowering therapy.
The use of machine-learning was found to detect familial hypercholesterolemia with high accuracy.
A causal relationship between HDL-C and gout was established.
Lipid-lowering pharmacotherapy targeting LDL-C was found to be safe and effective in reducing CV and cerebrovascular events, with similar efficacy in older and younger patients.
Adverse changes in cardiac structure and function were found to be associated with LDL-C and triglycerides plasma concentrations.
Statin therapy initiation after index revascularization in patients with peripheral arterial occlusive disease was associated with significant reductions in mortality and cardiovascular events.
A novel tool in which clinical risk factors and coronary artery calcium score are added to standard pre-test probability modeling was found to improve risk prediction in suspected obstructive coronary artery disease.
Atherosclerotic cardiovascular disease represents the top global cause of morbidity and mortality.
Elevated LDL-C levels in people ages 70 to 100 years were found to be associated with a higher absolute risk for myocardial infarction and atherosclerotic cardiovascular disease.